Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128850 | 1.00 | ALOX5 (0.41) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL6239782 | 1.00 | ALOX5 (0.41) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL6241067 | 0.88 | S1PR1 (0.44) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL6234620 | 0.88 | S1PR1 (0.44) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL6241350 | 0.85 | S1PR1 (0.45) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL6238590 | 0.78 | MMP1 (0.46) | ALOX5S1PR1S1PR5MAOBMAOA | |
| SCHEMBL7132752 | 0.77 | ADAM17 (0.54) | — | |
| SCHEMBL7133979 | 0.77 | ADAM17 (0.54) | — | |
| SCHEMBL6236695 | 0.77 | ADAM17 (0.54) | — | |
| SCHEMBL7132748 | 0.77 | ADAM17 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | ALOX5 3125/4885S1PR1 2147/4885S1PR5 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.